Top

Cancer Immunology, Immunotherapy

Published in:

01-01-2009 | Original Article

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

Authors: T. Schulze, W. Kemmner, J. Weitz, K.-D. Wernecke, V. Schirrmacher, P. M. Schlag

Published in: Cancer Immunology, Immunotherapy | Issue 1/2009

Abstract

Purpose

Metastatic disease is a major cause of mortality in colorectal cancer patients. Even after complete resection of isolated liver metastases, recurrence develops in the majority of patients. Therefore, development of strategies to prevent recurrent liver metastases is of major clinical importance. The present prospectively randomised phase III trial investigates the efficiency of active specific immunotherapy (ASI) after liver resection for hepatic metastases of colorectal cancer.

Methods

Patients with histologically confirmed liver metastases from colorectal cancer were randomised to the vaccination or control group. After complete resection of liver metastases, patients randomised to the vaccination group received six doses of Newcastle disease virus (NDV) infected autologous tumour cell vaccine (ATV-NDV). The primary end-point was overall survival, secondary end-points were disease-free survival and metastases-free survival.

Results

Fifty-one patients were enrolled in the study with 50 patients available for analysis. The follow-up period was 116.1 ± 23.8 month in the vaccination arm and 112.4 ± 18.5 month in the control group. In the total patient group, no differences in the primary and secondary end-points were detected. Most interestingly, subgroup analysis revealed a significant advantage for vaccinated colon cancer patients with respect to overall survival [hazard ratio: 3.3; 95%, confidence interval (CI): 1.0–10.4; P = 0.042] and metastases-free survival (hazard ratio: 2.7; 95%, CI: 1.0–7.4; P = 0.047) in the intention-to-treat analysis.

Conclusion

Active specific immunotherapy in unselected colorectal cancer patients was not effective for prevention of recurrent metastatic disease. However, in colon cancer patients, ASI with ATV-NDV appears to be beneficial prolonging overall and metastases-free survival.

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics. CA Cancer J Clin 55:10–30PubMedCrossRef

Ballantyne GH, Quin J (1993) Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 71:4252–4266PubMedCrossRef

Bengmark S, Hafstrom L (1969) The natural history of primary and secondary malignant tumors of the liver, I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23:198–202PubMedCrossRef

de Brauw LM, van de Velde CJ, Bouwhuis-Hoogerwerf ML, Zwaveling A (1987) Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 34:81–86PubMedCrossRef

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCrossRef

Foster JH (1978) Survival after liver resection for secondary tumors. Am J Surg 135:389–394PubMedCrossRef

Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241–1246PubMedCrossRef

Fernandez-Trigo V, Shamsa F, Sugarbaker PH (1995) Repeat liver resections from colorectal metastasis. Repeat hepatic metastases registry. Surgery 117:296–304PubMedCrossRef

Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980–985PubMedCrossRef

10.

Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, Brandi G (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 17:214–228CrossRef

11.

Lehner B, Schlag P, Liebrich W, Schirrmacher V (1990) Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine. Cancer Immunol Immunother 32:173–178PubMedCrossRef

12.

Haas C, Ertel C, Gerhards R, Schirrmacher V (1998) Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle disease virus. Int J Oncol 13:1105–1115PubMed

13.

Washburn B, Schirrmacher V (2002) Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 21:85–93PubMed

14.

Termeer CC, Schirrmacher V, Brocker EB, Becker JC (2000) Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7:316–323PubMedCrossRef

15.

Ertel C, Millar NS, Emmerson PT, Schirrmacher V, von Hoegen P (1993) Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 23:2592–2596PubMedCrossRef

16.

Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V (2002) Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 21:685–694PubMed

17.

Schirrmacher V, Bai L, Umansky V, Yu L, Xing Y, Qian Z (2000) Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol 16:363–373PubMed

18.

Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V, Walczak H (2003) TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 170:1814–1821PubMed

19.

Zeng J, Fournier P, Schirrmacher V (2002) Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 297:19–30PubMedCrossRef

20.

Lokuta MA, Maher J, Noe KH, Pitha PM, Shin ML, Shin HS (1996) Mechanisms of murine RANTES chemokine gene induction by Newcastle disease virus. J Biol Chem 271:13731–13738PubMedCrossRef

21.

Schirrmacher V (2005) Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54:587–598PubMedCrossRef

22.

Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacher V (1992) Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer, First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 35:325–330PubMedCrossRef

23.

Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr., Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350PubMedCrossRef

24.

Hoover HC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390–399PubMed

25.

Rimoldi M, Chieppa M, Salucci V, Avogadri F, Sonzogni A, Sampietro GM, Nespoli A, Viale G, Allavena P, Rescigno M (2005) Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 6:507–514PubMedCrossRef

26.

Johansson C, Kelsall BL (2005) Phenotype and function of intestinal dendritic cells. Semin Immunol 17:284–294PubMedCrossRef

27.

Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O’Connor T, Ward R (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122:1376–1387PubMedCrossRef

28.

Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B (1986) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 37:569–577PubMedCrossRef

Title: Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
Authors: T. Schulze
W. Kemmner
J. Weitz
K.-D. Wernecke
V. Schirrmacher
P. M. Schlag
Publication date: 01-01-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 1/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0526-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment

Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity

Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer

Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus

In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients

MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer